EUCTR2006-000564-81-IT进行中（未招募）1 期
A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer - Neoadjuv Lapat and/or Trastuz Treatm. Optimisation
GlaxoSmithkline R&D Ltd0 个研究点目标入组 455 人开始时间: 2007年12月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 455
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1) Female gender; 2) Age >=18 years; 3) Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1 (See Appendix 2 ); 4) Histologically confirmed invasive breast cancer: - Primary tumour greater than 2 cm diameter, measured by mammography and echography, - Any N, - No evidence of metastasis (M0) (isolated supraclavicular node involvement allowed); 5) Over expression and/or amplification of HER2 in the invasive component of the primary tumour according to one of the following definitions [Wolff et al 2006] and confirmed by a certified laboratory prior to randomisation (See section 5.2): ? 3+ over expression by IHC (> 30% of invasive tumour cells); ? 2+ or 3+ (in 30% or less neoplastic cells) over expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification; ? HER2 gene amplification by FISH/CISH ( > 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > than 2.2.) Patients with a negative or equivocal overall result (FISH test ratio of <2.2, < 6.0 HER2 gene copies per nucleus) and staining scores of 0, 1+, 2+ or 3+ (in 30% or less neoplastic cells) by IHC are not eligible for participation in the trial. Equivocal local results from non certified laboratories may be submitted for a final determination by the certified laboratory. ErbB2 status must be tested in local or regional certified laboratories prior to randomisation. If local FISH test is performed in non-certified laboratories, the PathVysion test (Vysis) or the INFORM HER2/neu test (Ventana Inc.) must be used, but will also need confirmation of the results by a certified laboratory. IHC overexpression scores obtained locally will also need confirmation in a certified laboratory to be considered as an entry criteria. Patients with negative local FISH/CISH tests (test ratio of < 1.8, < 4.0 ErbB2 gene copies per nucleus) or 0 and 1+ scores by IHC are not eligible for participation in the trial. Positive local FISH tests (>6 ErbB2 gene copies per nucleus, or a FISH ratio of more than 2.2) or 2/3+ overexpression by IHC obtained at non-certified local laboratories must be confirmed by some of the certified laboratories before randomisation; 6) Hormone receptor (HR) status: - Oestrogen Receptor (ER) status must be known. 7) Haematopoietic status: - Absolute neutrophil count > 1,5 x 10^9/L, - Platelet count > 100 x 10^9/L, - Hemoglobin at least 9 g/dl, 8) Hepatic status: - Bilirubin <= 2 x upper limit of normal (ULN), - AST and ALT <= 2.5 times ULN, - Alkaline phosphatase <= 2.5 times ULN, 9) Renal status: - Creatinine <= 2.0 mg/dL, 10) Cardiovascular: - Baseline LVEF >= 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan, 11) Negative serum pregnancy test, within 2-weeks (preferably 7 days) prior to randomization (For women of childbearing potential) 12) Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed) 13) Signed informed consent form (ICF) 14) Patient accepts to make available tumour samples for submission to central laboratory to conduct translational studies as part of this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
排除标准
- •1) Received any prior treatment for primary invasive breast cancer; 2) History of other malignancy. However, subjects with a past or current history of completely resected basal and squamous cell carcinoma of the skin or successfully treated in situ carcinoma of the cervix are eligible; 3) Diagnosis of inflammatory breast cancer; 4) Bilateral cancer; 5) Multi-focal cancer; 6) Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, uncontrolled hypertension (>=180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic therapy with oxygen; 7) Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject?s safety; 8) Unresolved or unstable, serious adverse events from prior administration of another investigational drug; 9) Active or uncontrolled infection; 10) Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF; 11) Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded; 12) Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies); 13) Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; 14) Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab or lapatinib or their excipients; 15) Pregnant or lactating women; 16) Concomitant use of CYP3A4 inhibitors or inducers (see Section 7.2 for list of prohibited medications).
研究者
相似试验
进行中（未招募）
不适用
A phase III multicentre, randomized open-label study of Revlimid (lenalidomide) plus dexamethasone (ReDex) versus observation in patients with smoldering multiple myeloma (MM) at high risk of progression to symptomatic MM - QuiReDexSmoldering multiple myeloma (MM) at high risk of progression to symptomatic MMEUCTR2007-000649-36-PTFundación PETHEMA120
进行中（未招募）
不适用
An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive advanced gastric cancer.Advanced gastric cancerMedDRA version: 7.1Level: PTClassification code 10017767EUCTR2005-000387-39-BEHoffmann-La Roche Ltd/Inc/AG/Roche Global Development584
进行中（未招募）
不适用
An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive advanced gastric cancer.EUCTR2005-000387-39-ITF. Hoffmann - La Roche Ltd. Pharmaceuticals Division, PDR584
进行中（未招募）
不适用
An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive advanced gastric cancer.EUCTR2005-000387-39-DKHoffmann-La Roche Ltd/Inc/AG/Roche Global Development584
进行中（未招募）
不适用
An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive advanced gastric cancer.EUCTR2005-000387-39-DEF. Hoffmann-La Roche Ltd.584